Business description
CureVac is a global clinical-stage biopharmaceutical company in the field of messenger RNA (mRNA) technology with expertise in developing and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of prophylactic vaccines, cancer therapies, antibody therapies and the treatment of protein therapies. CureVac is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA.
Management board & Supervisory board
| CEO |
| Franz-Werner Haas |
| Management board |
| Pierre Kemula, Dr. Antony Blanc, Dr. Igor Splawski, Dr. Malte Greune, Klaus Edvardsen |
| Supervisory board |
| Baron Jean Stéphenne, Craig A. Tooman, Dr. Chris Tanner, Dr. Friedrich von Bohlen und Halbach, Dr. Mathias Hothum, Dr. Ralf Clemens, Dr. Viola Bronsema |
Company data
| Name: |
Curevac N.V. |
| Address: |
Friedrich-Miescher-Str. 15,DE-72076 Tübingen |
| Phone: |
+49-7071-9883-0 |
| Fax: |
+49-7071-9883–1101 |
| E-mail: |
info@curevac.com
|
| Internet: |
https://www.curevac.com/ |
| Industry: |
Biotechnology |
| Sector: |
Biotechnology |
| Sub sector: |
Biotechnology |
| End of financial year: |
12-31 |
| Free Float: |
- |
| IPO date: |
- |
Investor relations
| Name: |
Dr. Sarah Fakih |
| IR phone: |
+49-7071-9883-1298 |
| IR Fax: |
- |
| IR e-mail: |
investors@curevac.com
|
